This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
ACE Inhibitor Related Topics 
DAIC
APRIL 9, 2024
The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.
105 
HeartRhythm
DECEMBER 31, 2024
Curtain etal1 performed an analysis of the VALIANT (Valsartan in Acute Myocardial Infarction) and PARADISE-MI (Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) trials to evaluate whether risk of sudden cardiac arrest (SCA) following acute myocardial infarction (MI) has changed over time.
American College of Cardiology
APRIL 8, 2024
24 in Atlanta.
NEJM Journal Watch - Cardiology
JANUARY 3, 2024
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
American College of Cardiology
AUGUST 1, 2024
Can patients with advanced chronic kidney disease (CKD) be initiated on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) without increasing their risk for needing kidney failure replacement therapy?
Dr. Paddy Barrett
NOVEMBER 29, 2024
Most people with high blood pressure will be treated with an ACE inhibitor, ARB, calcium channel blocker or a diuretic. 6 Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. There are others also.
JAMA Cardiology
AUGUST 6, 2024
This secondary analysis of the Valsartan in Acute Myocardial Infarction (VALIANT) and Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) randomized clinical trials investigates the changes over time in sudden death rate after myocardial infarction and the characteristics of people (..)
Cardiology Update
AUGUST 4, 2024
This includes beta-blockers, ACE inhibitors, ARBs, ARNIs, MRAs, and SGLT2 inhibitors. The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).
119 
ECG Guru
MARCH 6, 2024
Capoten (captopril) is an ACE inhibitor. The Patient: Unfortunately, this is an old tracing, and we do not have patient information, other than the list of medications the patient has been taking, (Lasix, Capoten, Ntg, and Procardia). Lasix (furosemide) is a potassium – wasting diuretic.
98 
American College of Cardiology
MARCH 6, 2024
The goal of the PARADISE-MI trial was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction (AMI) population.
Open Heart
DECEMBER 6, 2023
received ACE inhibitors or aldosterone receptor blockers (ACEIs/ARBs), 54.4% (CI 45.4 On random effects meta-analysis, 92.1% (95% CI 89.3 received at least one antiplatelet, 78.0% (CI 73.5 received beta-blockers, 58.7% (CI 52.3 were screened for fibromuscular dysplasia (FMD), and 70.2% (CI 60.8
98 
MIBHS
FEBRUARY 15, 2025
Common medications include diuretics, ACE inhibitors, beta-blockers, and calcium channel blockers. Follow Your Doctors Advice : If lifestyle changes arent enough, your doctor may prescribe medications to manage your blood pressure.
The American Journal of Cardiology
AUGUST 8, 2024
Publication date: Available online 7 August 2024 Source: The American Journal of Cardiology Author(s): Johanna A. van der Zande, Karishma P. Ramlakhan, Katja Prokselj, Edison Muñoz-Ortiz, Amalia Baroutidou, Magdalena Lipczynska, Edit Nagy, Tobias Rutz, Arie Franx, Roger Hall, Mark R. Johnson, Jolien W. Roos-Hesselink, ROPAC investigators
Heart BMJ
OCTOBER 28, 2024
Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic.
59 
Heart BMJ
JANUARY 10, 2024
Time-updated adjusted Cox regression models were used to compare patients with and without RAS inhibitors. Subgroup analyses were performed, as well as a comparison between angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Both treatment with ACE inhibitors (aHR 0.89 (95% CI 0.82
40 
Open Heart
APRIL 24, 2024
were on a beta blocker and on an ACE inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, respectively. During the second period, and following the consultation, of the patients with HF with reduced ejection fraction (HFrEF), 86.4%
Conquering CHD
JUNE 20, 2023
ACE Inhibitors WHAT THEY DO : ACE inhibitors block the angiotensin-converting enzyme (ACE) which causes narrowing of blood vessels. COMMON NAMES : Some common brand name ACE inhibitor drugs available to patients with CHD include lisinopril, ramipril and enalapril.
Open Heart
NOVEMBER 8, 2023
Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.
MIBHS
OCTOBER 31, 2024
Medications Medications are often the first line of treatment for cardiomegaly and can include: ACE inhibitors or ARBs , which help lower blood pressure and reduce the workload on the heart. The primary goals of treatment are to address the root cause, reduce the heart’s workload, and prevent complications like heart failure.
Heart BMJ
MARCH 12, 2024
The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences. Recurrences of TTS are not infrequent and there is no standard preventive therapy.
Journal of Clinical Investigation - Cardiology
FEBRUARY 3, 2025
In silico analysis of FDA-approved drugs led to the identification of an ACE inhibitor, ramipril, that protected against sunitinib-induced vascular dysfunction in vitro and in vivo, all while preserving the efficacy of cancer therapy.
DAIC
APRIL 6, 2024
The composite rate of total heart failure hospitalizations and death from heart failure was also 31% lower among those receiving empagliflozin.
98 Heart BMJ
DECEMBER 15, 2023
At multivariable analysis, smoking habit (OR 2.28; p<0.0001), history of traumatic syncope (OR 2.29; p=0.0001) and ACE inhibitors/angiotensin II receptor blockers (OR 4.74; p<0.0001) were independently associated with SS. Patients with SS were older (48.8±20.0 ±20.0 ±19.1, vs 47.7%, p=0.001).
The British Journal of Cardiology
JANUARY 16, 2024
Twenty years ago, Wald and Law 1 hypothesised that, if a combination pill could be made including aspirin, folic acid, a statin, and a low-dose diuretic, beta blocker and angiotensin-converting enzyme (ACE) inhibitor (thus, allowing for the simultaneous modification of four different risk factors: low-density lipoprotein [LDL]-cholesterol, blood pressure, (..)
Stroke Journal
FEBRUARY 1, 2024
White with interaction by prevalent stroke status, adjusted for demographic and socioeconomic status.Results:Of 17,222 participants without prevalent stroke at Visit 1, Black participants had greater odds of ACE-inhibitor usage relative to White participants (OR 1.68, 95% CI 1.44-1.95).
Open Heart
APRIL 7, 2022
Those with sinus tachycardia were treated with beta-blockers and those with ventricular hypertrophy received a beta-blocker and ACE-inhibitor combination. This provided comprehensive rhythm surveillance and automatic downloads of all detections to a monitoring station for cardiology interpretation.
40 
Circulation
NOVEMBER 11, 2024
Cardiac MRI did not show significant ischemic findings.The patient received medical therapy consisting of antiplatelet agents, high dose statin, beta blocker and ACE inhibitor, as well as diuretics. Notably, the LAD had multiple aneurysmal segments and areas of eccentric stenosis upto 90%.Multislice
DAIC
APRIL 6, 2024
The composite rate of total heart failure hospitalizations and death from heart failure was also 31% lower among those receiving empagliflozin.
81 
Open Heart
FEBRUARY 17, 2024
were on ACE inhibitors/angiotensin receptor blockers and 54.9% Results A total of 237 participants were included in the final analysis. The mean age was 61.3±17.36 years, and the majority (57.8%) were male participants. on beta-blockers.
European Journal of Heart Failure
NOVEMBER 29, 2023
Methods and results Patients ( n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death.
Circulation
NOVEMBER 11, 2024
Women received more discharge cardiac medications than men: antiplatelet agents, statins, beta blockers, ACE inhibitors, angiotensin II blockers, calcium channel blockers, and nitrates (p=0.0002 - 0.04).Follow-up Length of stay (LOS) in the CPU to discharge was 10.4
40 
Physiologically Speaking
MARCH 6, 2024
ACE inhibitors block the angiotensin-converting enzyme to reduce blood pressure. Defining an exercise pill Experts who have commented on the idea of an exercise pill note one glaring issue: the term “exercise mimetic” is a not only a misnomer, but it’s inaccurate and misleading. Statins lower cholesterol.
92 
EMS 12-Lead
APRIL 14, 2022
ACE inhibitors, or potassium-sparing diuretics), are particularly susceptible. A brief review of the pathophysiology of hyperkalemia will help set the stage for the ECG changes inherent therein. Other causes include metabolic acidosis, in which hydrogen ions shift into the cells in exchange for potassium.
EMS 12-Lead
MAY 8, 2022
ACE inhibitors, or potassium-sparing diuretics), are particularly susceptible. This ECG is pathognomonic for hyperkalemia. Predisposition to hyperkalemia is complex, but in general, patients with renal disease, or those taking medications that yield potassium retention (e.g.
Dr. Smith's ECG Blog
NOVEMBER 15, 2023
associated typical Myocardial Infarction therapies such as statins and ACE inhibitors with significantly decreased 1 year mortality in MINOCA patients, which suggests that they do indeed have a similar pathophysiology to MI patients with obstructive coronary disease. Lindahl et al.
Dr. Malcolm Kendrick
OCTOBER 20, 2023
Whilst we had evidence (from drug company sponsored clinical trials) demonstrating that certain actions e.g., taking an ACE-inhibitor after a heart attack, reduced the risk of future heart attacks. I had many concerns, but I will just stick to one here. Or, if the interactions between all four drugs might cancel out any benefit.
52 
Dr. Sanjay Gupta
MARCH 6, 2022
These include ACE inhibitors (medications such as ramipril, lisinopril, perindopril etc), beta-blockers (carvedilol, Bisoprolol, nebivolol), aldosterone antagonists (spironolactone), Entresto and now there is a new class of medications called SGLT2 inhibitors such as Dapagliflozin.
Dr. Smith's ECG Blog
SEPTEMBER 30, 2019
The patient stated he had a long history of well-controlled hypertension for which he was compliant with his ACE-inhibitor. His pain radiated to his shoulders throughout the evening and the night but it did not prompt him to seek medical attention. He was also treated for erectile dysfunction but had not taken any medications recently.
52 Dr. Sanjay Gupta
MAY 23, 2022
We now do have some really good medications that help do both and these include: ACE Inhibitors/Entresto Beta Blockers MRAs – Mineraloreceptor antagonists SGLT2 inhibitors And ideally anyone with heart failure should be on all these medications unless they are intolerant or in some way the medications are contraindicated.
The British Journal of Cardiology
JULY 17, 2024
“In spite of the accumulating evidence of their efficacy, established treatments for maintaining renal function remain woefully underutilized. Clinicians and health care systems must be encouraged to make use of these treatments.”
Dr. Sanjay Gupta
DECEMBER 19, 2022
Another problem is that sometimes if you have myocardial involvement I.e
40 
Dr. Sanjay Gupta
MARCH 6, 2022
These include ACE inhibitors (and now a medication called Entresto), beta blockers, Mineralocorticoid receptor antagonists and now a new class of anti-diabetic medications called SGLT2 inhibitors and ideally wherever possible the patient should try and take a little of all of them as opposed to taking lots of one and none of the others.
Dr. Smith's ECG Blog
NOVEMBER 30, 2022
associated typical Myocardial Infarction therapies such as statins and ACE inhibitors with significantly decreased 1 year mortality in MINOCA patients, which suggests that they do indeed have a similar pathophysiology to MI patients with obstructive coronary disease. Lindahl et al.
52 
Circulation
NOVEMBER 11, 2024
Methods:We analyzed data of ACE inhibitor naïve subjects with heart failure due to congenital heart disease (n=31) or dilated cardiomyopathy (n=3) from the prospective, open-label, multicenter phase II/III pharmacokinetic bridging studies using NONMEM®.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content